Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Paul A. Mahon, Executive Vice President and General Counsel at United Therapeutics Corp (NASDAQ:UTHR), a $12.76 billion market cap company with impressive gross profit margins of 89%, sold 11,490 shares of common stock on June 26, 2025, for a total value of $3.14 million. The sales were executed at prices ranging from $284.1029 to $288.8 per share. According to InvestingPro analysis, the company currently appears undervalued, trading at a P/E ratio of 10.46 and near its 52-week low.
On the same day, Mahon also exercised stock options for 11,000 shares of United Therapeutics common stock at a price of $135.42, resulting in a total value of $1489619.
These transactions were executed pursuant to a pre-arranged 10b5-1 trading plan entered into on December 24, 2024. Following these transactions, Mahon directly owns 36,781 shares of United Therapeutics Corp.
In other recent news, United Therapeutics Corporation has completed enrollment for its phase 3 ADVANCE OUTCOMES study evaluating ralinepag as a treatment for pulmonary arterial hypertension (PAH). The study enrolled 728 participants, with top-line data expected in the first half of 2026. Meanwhile, Insmed (NASDAQ:INSM) Incorporated announced positive topline results from its Phase 2b study of Treprostinil Palmitil Inhalation Powder (TPIP) for PAH, meeting its primary and all secondary efficacy endpoints. Insmed plans to engage with the FDA for Phase 3 trial design, with studies anticipated to begin before the end of 2025. In related developments, Leerink Partners reaffirmed their Outperform rating for United Therapeutics, citing potential advantages of the company’s Tyvaso as a new inhaled therapy for idiopathic pulmonary fibrosis (IPF). Raymond (NSE:RYMD) James maintained a Strong Buy rating for Liquidia Technologies (NASDAQ:LQDA) following a favorable court ruling, which allows for the commercialization of Yutrepia for PAH. Additionally, TD Cowen reiterated a Buy rating for United Therapeutics, highlighting confidence in Tyvaso’s prospects for treating IPF and the potential of the company’s xenotransplantation platform. These developments reflect ongoing advancements and strategic movements within the biopharmaceutical sector, with significant implications for PAH and IPF treatments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.